Clinical Trials Using Talimogene Laherparepvec

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Talimogene Laherparepvec. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-16 of 16
  • Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)

    Phase 1b Subjects will be treated with talimogene laherparepvec until all injectable tumors have disappeared, disease progression per modified Immune-Related Response Criteria (irRC), or intolerance of study treatment, up to a maximum of 24 months of study treatment. Subjects will be treated with MK-3475 (pembrolizumab) until complete response (CR) disease progression per irRC, or intolerance of study treatment, up to a maximum of 24 months of study treatment. In Phase 3, Subjects will be treated with talimogene laherparepvec plus pembrolizumab(arm 1) or placebo plus pembrolizumab (arm 2) until 24 months from the date of the first dose of pembrolizumab or end of treatment due to disappearance of injectable lesions, complete response, disease progression per irRC-RECIST or intolerance of study treatment.
    Location: 15 locations

  • Study of Talimogene Laherparepvec In Children With Advanced Non-CNS Tumors

    This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection
    Location: 4 locations

  • PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

    This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma in patients who (1) are not candidates for targeted therapy and (2) are not candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine (DTIC), temozolomide (TMZ) or intralesional talimogene laherparepvec as determined by Investigator preference and standard of care in the Investigator's country or region. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms.
    Location: 5 locations

  • Talimogene Laherparepvec, Capecitabine, and Chemoradiation before Surgery in Treating Patients with Locally Advanced or Metastatic Rectal Cancer

    This phase I trial studies the best dose and side effects of talimogene laherparepvec in combination with capecitabine and chemoradiation before surgery in treating patients with rectal cancer that has spread from where it started to nearby tissue and lymph nodes. Drugs used in immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Drugs used in chemotherapy, such as capecitabine, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving talimogene laherparepvec, capecitabine, and chemoradiation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: 2 locations

  • Talimogene Laherparepvec with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

    This phase II trial studies the side effects of talimogene laherparepvec and to see how well it works with or without hypofractionated radiation therapy in treating patients with skin melanoma, Merkel cell carcinoma, or other solid tumors that have spread to places not suitable for surgical removal. Drugs used in the immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if giving talimogene laherparepvec with or without hypofractionated radiation therapy will work better in treating patients with cutaneous melanoma, Merkel cell carcinoma, or solid tumors.
    Location: 2 locations

  • Talimogene Laherparepvec in Treating Patients with Locally Advanced, Metastatic, or Refractory Pancreatic Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of talimogene laherparepvec in treating patients with pancreatic cancer that cannot be removed by surgery and has spread from where it started to nearby tissue, lymph nodes, or to other places in the body, or that does not respond to treatment. Talimogene laherparepvec may help infect and kill tumor cells and activate the body’s own immune cells to destroy the tumor cells throughout the body.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Sarcoma

    This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with sarcoma that has spread to other places in the body. Talimogene laherparepvec may cause tumor cell death directly in the area of tumor that it is injected into and help the immune system to recognize and destroy tumor cells present at other sites in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with sarcoma.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    This phase II trial studies how well talimogene laherparepvec works and nivolumab in treating patients with lymphomas that do not responded to treatment or non-melanoma skin cancers that have spread to other places in the body or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as nivolumab, may block a protein needed by tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better in treating patients with lymphomas or non-melanoma skin cancers.
    Location: 2 locations

  • Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Stage III-IV Melanoma

    This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
    Location: SWOG, Portland, Oregon

  • Talimogene Laherparepvec and Combination Chemotherapy in Treating Patients with Triple Negative Breast Cancer before Surgery

    This phase I / II trial studies the best dose and how well talimogene laherparepvec works with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide in treating patients with triple negative breast cancer before surgery. Drugs used in the immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talimogene laherparepvec and combination before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Talimogene Laherparepvec in Treating Patients with Recurrent Breast Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors

    This is a phase 1, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec, injected intrahepatically, into liver tumors with known progression in subjects with Hepatocellular carcinoma and subjects with liver metastases from breast adenocarcinoma, colorectal adenocarcinoma, gastroesophageal cancer (adenocarcinoma or squamous cell carcinoma), melanoma, non-small cell lung cancer, or clear cell renal cell carcinoma. The study consists of 2 parts and 2 groups. Part 1 is a 3+3 dose escalation consisting of 3 sequential dose cohorts each administering talimogene laherparepvec in increasing dose concentrations and dose volumes. In Part 1, the Maximum Tolerated Dose determination of non-hepatocellular carcinoma liver metastases (Group A) will be evaluated separately from hepatocellular carcinoma (Group B), and each dose cohort will need to be deemed safe for non-hepatocellular carcinoma subjects before it will be administered in hepatocellular carcinoma subjects. Part 2 consists of expansion cohorts administering the Maximum Tolerated Dose of talimogene laherparepvec determined from Part 1 for Groups A (non-hepatocellular carcinoma) and B (hepatocellular carcinoma) to approximately 10 subjects for each tumor type.
    Location: 3 locations

  • Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery

    This phase Ib / II trial studies the side effects and best dose of talimogene laherparepvec when given together with radiation therapy before surgery (preoperative) in treating patients with soft tissue sarcoma that has spread from where it started to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery. Talimogene laherparepvec is a modified herpes simplex type-1 virus (the “cold sore” virus) that has had its genes modified in a laboratory so that it produces a protein called human granulocyte macrophage colony-stimulating factor and multiplies and grows in tumor cells. Talimogene laherparepvec may be able to destroy cells in the injected tumors and activate the body’s own immune cells to destroy the tumor cells throughout the body, not just the area where it is injected. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talimogene laherparepvec together with radiation therapy prior to surgery may be a better treatment for soft tissue sarcomas.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

    Up to 36 subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland. The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Talimogene Laherparepvec and Radiation Therapy in Treating Patients with Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

    This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.
    Location: Mayo Clinic Cancer Center LAO, Rochester, Minnesota

  • Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

    A Phase 1b / 3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Location: 5 locations